THIRD AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTGpex® Development and Manufacturing Agreement • March 19th, 2024 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This Third Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 11th day of April 2022 (“Amendment Effective Date”), by and between DiaMedica Therapeutics, Inc., a Manitoba corporation, with a place of business at 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
